stars 1 stars 2 stars 3

Seraxis is bringing transformative therapies to the millions of people worldwide struggling with the management of insulin-requiring diabetes and the associated life-threatening complications. Seraxis’ lead program, SR-02, is a novel islet replacement therapy for patients of insulin-requiring diabetes with concurrent immunosuppression therapy. This therapy is the foundation of Seraxis follow-on therapies for patients without immune suppression. Frazier Life Sciences, Polaris Partners, Eli Lilly and Company, the T1D Fund and others are investors in Seraxis.

Seraxis Questions

The Seraxis annual revenue was $6 million in 2026.

William Rust is the Founder and CEO of Seraxis.

11 people are employed at Seraxis.

Seraxis is based in Germantown, Maryland.

The NAICS codes for Seraxis are [54, 5417, 541714, 541, 54171].

The SIC codes for Seraxis are [87, 873].

Top Seraxis Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users